Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
2019 ◽
Vol 394
(10212)
◽
pp. 1915-1928
◽
Keyword(s):
Phase 3
◽